Below is a list of all the studies that have been conducted at Raleigh Neurology Associates from 1997 to present. These are all multi-center clinical trials that have investigated a wide variety of illnesses and medications.
By enrolling in these studies, each patient has contributed to the advancement of medical science and we appreciate the time, dedication and effort given by those who have participated in the trials. Even those studies which have proven to be negative, have brought the scientific community invaluable knowledge of what not to do.
Some of the studies were short in duration, but many required a long-term commitment on the part of the patients. We are grateful for their willingness to be a part in this process of developing future treatments that will benefit the healthcare of subsequent patients.
If you'd like further information on the completed studies, including published studies, please contact Jane K. Downs, Research Director at 919-420-1659 or jdowns@raleighneurology.com.
ALZHEIMER'S DISEASE | CHRONIC PAIN | EPILEPSY | MIGRAINE |
MULTIPLE SCLEROSIS | PARKINSON'S DISEASE | POST HERPETIC NEURALGIA |
RESTLESS LEG SYNDROME |SLEEP DISORDERS | STROKE | OTHER STUDIES
Alzheimer's Disease
A 54-week, double-blind, randomized, placebo-controlled, parallel group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE-4-stratified subjects with mild to moderate Alzheimer's disease (REFLECT 3)
(GlaxoSmithKline) A 54-week, double-blind, randomized, placebo-controlled, parallel group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE-4-stratified subjects with mild to moderate Alzheimer's disease (REFLECT 2)
A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (A2020) in Patients with Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period, Eisai, 2003.
Saegis Mild to moderate Alzheimer’s disease: A multi-center, randomized, double-blind, placebo-controlled, Phase II study of efficacy and safety of SGS742-CL02 in patients with mild to moderate Alzheimer’s Disease.
A Double-Blind Placebo-Controlled Study of VP4896 for the Treament of Mild-to-Moderate Alzheimer's Disease.
A Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer’s Type
Back to Top
Chronic Pain
A 4-week randomized, multi-center, double-blind, placebo- and active-controlled parallel-arm, forced-titration Phase llB study comparing efficacy and safety of ascending doses of CG5503 prolonged-released (PR) up to 233mg BID and oxycodone controlled-release (CR) up to 20mg BID to placebo in patients with moderate to severe chronic pain due to osteoarthritis of the knee.
A Double Blind Randomized, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of 4 Doses of Intramuscular Phenoxybenzamine Hydrochloride Injection verses Placebo in Chronic Muscle Pain; Berlex Laboratories, 1998
ARC 2063115 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Study of the Analgesic Efficacy and Safety of Single and Repeated Administration of 2G IV Propacetamol for the Treatment of Post-Operative Pain following Lower Abdominal Surgery, UPSA (France), 1998
A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Groups Study of Morphelan (morphine sulfate oral extended release capsules) in Patients with Chronic, Moderate to Severe Pain; Targon Corporation, 1998.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Clinical Study of the Safety and Efficacy of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex Injections into Areas of Focal Tenderness in Subjects with Chronic Low Back Pain; Allergan, 1998.
A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Efficacy and Safety Of Topirmate Verses Placebo In The Treatment Of Pain Associated with Diabetic Peripheral Polyneuropathy; The R. W. Johnson Pharmaceutical Research Institute, 2000
A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topirmate Verses Placebo in the Treatment of Pain Associated with Diabetic Peripheral Polyneuropathy; The R. W. Johnson Pharmaceutical Research Institute, 2001
Evaluation of the Efficacy and Safety of Numorphan CR (Oxymorphone HCI Controlled Release) Relative to Placebo and OxyContin (Oxycodone HCI Controlled Release) in Subjects with Chronic Low Back Pain, Endo Pharmaceuticals, Inc., 2001
"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of 2 Different Doses of EpiCept-NP Topical Cream (ketamine/amitriptyline combination) Applied 2 Times Daily in the Treatment of Postherpetic Neuralgia." (PHN) EpiCept Corporation, 2002
Back to Top
Epilepsy
PROTOCOL LAM 100036: A multi-center, double-blind, randomized, parallel-group evaluation of LAMICTAL Extended-Release Adjunctive Therapy in patients with primary generalized tonic-clonic seizures.
PROTOCOL CAPSS-272: A double-blind trial comparing the efficacy, tolerability and safety of Monotherapy Topiramate versus Phenytoin in subjects with seizures indicative of new onset Epilepsy.
Open Randomized Comparison of Add-On Lomotrigine or Valproate/Carbamazepine withdrawing to Monotherapy in Patients with Treatment Resistant Epilepsy; Glaxo Wellcome, 1997.
An Open-Label Pilot Comparison of Lamotrigine Versus Divalproex Sodium for the Treatment of Patients with Juvenile Myoclonic Epilepsy; Glaxo Wellcome, 1999.
Pregabalin BID Open-Label Add-On Trial : An Open Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures; Parke-Davis, 1999
Randomized, Double-Blind, Parallel Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topirmate in the Treatment of Newly Diagnosed or Recurrent Epilepsy; The R. W. Johnson Pharmaceutical Research Institute, 2000
A Randomized, Double-Blind, Parallel Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topirmate in the Treatment of Newly Diagnosed or Recurrent Epilepsy; The R. W. Johnson Pharmaceutical Research Institute, 2001
PROTOCOL LAM100118: An open label evaluation of LAMICTAL Monotherapy for the treatment of newly-diagnosed typical Absence seizures in children and adults.
PROTOCOL LAM 100034: A multi-center, double-blind, randomized, parallel-group evaluation of LAMICTAL extended-release adjunctive therapy in subjects with partial seizures
Back to Top
Migraine and Other Headaches
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramte for the Prophylaxis of Migraine in Pediatric Subjects 12 - 17 Years of Age
Divalproex Sodium Extended-Release Tablets for Migraine Prophylaxis in Adolescents: An Open-label, Long-Term Safety Study
A Randomized, Double-Blind, Placebo-Controlled, Parrallel-Group, Dose-Ranging, Multicenter study of the Efficacy of RWJ 333369-MIG-2001
A randomized, double-blind, placebo-controlled study of oral Almotriptan 6.25 mg, 12.5 mg, and 25 mg in the acute treatment of migraine in adolescents.
A randomized, double-blind, parallel group, placebo-controlled, single attack evaluation of the efficacy and tolerability of Trexima (sumatriptan 85 mg / naproxen sodium 500 mg) tablets vs. placebo when administered during the mild pain phase of a migraine.
A Multi-Center, Double-Blind, Randomized, Parallel Group, Single-Dose, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of Excedrin Extra-Strength in Alleviating the Headache Pain of an Acute Migraine Attack: Bristol-Myers, 1997.
A 12-month Study of VML in the Acute Treatment of Migraine: Vanguard Medica Ltd. 1997.
Multicenter, Long Term Study to Maximize Migraine Relief with 311C90 Maximm; Zeneca and Glaxo Wellcome, 1997.
A Randomized, Double-Blind, Double-Dummy, Active-Placebo Controlled, Parallel Group Evaluation of Oral Naratriptan (2.5 mg) Compared to Oral Naproxen Sodium (275 mg) on Migraine-Related Quality of Life; Glaxo Wellcome, 1997
Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Acetaminophen 1000 mg for the Treatment of Migraine Headache Pain; McNeil Consumer Products Company, 1998
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of Sumatriptan 50mg and 100mg Tablets Administered During the Mild Pain Phrase of Menstrually-Associated Migraine Attack, GlaxoSmithKline, 2001
A Randomised, Double-Blind, Placebo-Controlled, In-Clinic Pilot Study to Investigate the Efficacy and Tolerability of 100mg Sumatriptan Administered as a Film-Coated, Fast Disintegrating Tablet, 2002.
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (Zomig) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine (311CUS/0022:0204), Astra-Zeneca, 2003
A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Two Dose Levels (5mg and 20mg) of Sumatriptan Nasal Spray in the Acute Treatment of a Single Migraine Attack in Adolescent Migraineurs (12 - 17 Years of Age), 2002
Long-Term, Open - Label Safety of Oral Almotriptan Malate 12.5 mg in the Treatment of Migraine in Adolescents
Back to Top
Multiple Sclerosis
14 week double-blind, placebo controlled parallel group study to evaluate safety and efficacy of oral Fampridine-SR (10 mg bid) in patients with MS with definite extension. 2nd Phase 3 study for MS patients with impaired walking and leg weakness to promote muscle strength, walking and endurance.
A Randomized, Double-Blind, Placebo-Controlled, Dose Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment
14 week double-blind, placebo controlled parallel group study to evaluate safety and efficacy of oral Fampridine-SR (10 mg bid) in patients with MS with definite extension. 2nd Phase 3 study for MS patients with impaired walking and leg weakness to promote muscle strength, walking and endurance.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study of Subcutaneous Tovaxin in Subjects with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
A 12-Month Double-Blind, Randomized, Multicenter, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily versus Interferon b-1a (Avonex) administered i.m. once weekly in Patients with Relapsing-Remitting Multiple Sclerosis with Optional Extension Phase
A Phase II, double-blind, placebo-controlled, randomized, dose-ranging study of Multiple Subcutaneous Injections of Human Monoclonal Antibody in subjects with relapsing-remitting Multiple Sclerosis.
Protocol Rituximab U2786g. A Phase II/III, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the safety and efficacy of Rituximab in adults with Primary Progressive Multiple Sclerosis.
Protocol Rituximab U2787g. A Phase II, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the safety and efficacy of Rituximab in Adults with Relapsing- Remitting Multiple Sclerosis.
MULTIPLE SCLEROSIS (PROTOCOL ACT C-865): A multi-center, randomized, blinded, parallel-group study of AVONEX compared with AVONEX in combination with oral Methotrexate, intravenous Methylprednisilone, or both in subjects with relapsing-remitting Multiple Sclerosis who have breakthrough disease on Avonex Monotherapy.
A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of NBI-5788 in patients with relapsing Multiple Sclerosis.
African American Genetic Study to Determine the Genetic Susceptibility of Patients to Multiple Sclerosis; University of Western Ontario, 1999
A Placebo-Controlled, Double-Blind, Randomized, Parallel Groups, Single Dose Study to Assess Efficacy and Safety of Tizanidine Hydrochloride-Modified Release in Patients with Spasticity due to Multiple Sclerosis or Spinal Cord Impairment Treated with 24 or 48 mg; Elan Pharmaceuticals, Inc. 2000
Pilot MRI Study of PEG-Intron (SCH 54031) in Ambulatory Subjects with Relapsing Multiple Sclerosis; Schering-Plough Research Institute, 2000
"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex, in subjects with Relapsing-Remitting Multiple Sclerosis." Biogen, 2002
C-1803: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Safety Study of Natalizumab in combination with Glatiramer Acetate (GA) in Subjects with Relapsing-Remitting Multiple Sclerosis (MS), Biogen, 2003
A Multi-center, Randomized, Blinded, Parallel-Group Study of Avonex Compared with Avonex in Combination with Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects with Relapsing-Remitting Multiple Sclerosis who have Breakthrough Disease on Avonex Montherapy, Cleveland Clinic, 2004
A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients with Multiple Sclerosis, 2003.
An Open-Label Multicenter Study to Assess the Safety of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Patients with Pseudobulbar Affect, 2003
An Open-labeled, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects with Multiple Sclerosis Who Have completed Studies C-1801, C1802, or C-1803 Biogen Idec, 2004
Back to Top
Parkinson's Disease
A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s Disease.
A randomized, double-blind, placebo-controlled study of the efficacy and safety of trimethobenzamide (Tigan®) in the control of nausea and vomiting during initiation and continue treatment with subcutaneous apomorphine (Apokyn®) in apomorphine-naïve patients with Parkinson’s Disease suffering from acute intermittent “off” episodes, with phased withdrawal of patients from Tigan® to placebo.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.
A Multicenter, Randomized, Double-Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson's Disease.
Title: REQUIP 228. A two year phase 3b randomized, multi-center, double-blind sinemet-controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release Ropinerole add-on therapy to l-dopa at increasing the time to onset of Dyskinesia in Parkinson’s Disease subjects.
Schwarz Biosciences Protocol SP 824. A Phase 3B, Open-Label, Multicenter, Multinational Trial to Access the Tolerability of Switching Subjects from Ropinerole, Pramipexole, or Cabergoline to the Rotigotine Transdermal System and its Effect on Symptoms in Subjects with Idiopathic Parkinson’s Disease
Schwarz Biosciences Protocol SP 833. A Multicenter Multinational, Phase 3B Open-Label Extension Trial to Access the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects with Idiopathic Parkinson’s Disease
A Phase III Multicenter, Double Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 MG BID or 100 MG BID on the Progression of Parkinson"s Disease in Patients Treated with L-Dopa of Dopamine Agonist, Aventis, 2001
An Open Label Study to Evaluate the Long-Term Safety an Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of "Off" Episodes in Patients with "On-Off" of "Wearing-Off" Effects Associated with Late-Stage Parkinson's Disease, Mylan Pharmaceuticals, Inc., 2001
A Phase III, Double-Blind, Placebo-controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients with Early Parkinson's Disease, Protocol 666E-CNS-0075-021, Pharmacia-Upjohn, 2001
A Multicenter Open-Label Study To Evaluate Different Dosage Regimens Of Levodopa/DDCI/Entacapone Combination In Patients With Parkinson's Disease Who Start To Experience End-Of-Dose "Wearing-Off" Symptoms, Entacapone/Comtan Protocol No. CCOM998 IA04, Novartis 2001
Protocol 666E-CNS-0614-001: Pharmacogenomics Blood Sampling Protocol for Sumanirole, Pfizer, 2001
Sumanirole M/2760/0011, PNU-95666E: Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability, and Therapeutic Response in Patients with Parkinson's Disease, Pfizer, 2001
A Prospective, Randomized, Placebo-Controlled, Parallel Groups Study of the Continued Efficacy and Safety of Subcutaneous Injections of Apomorphine in the Treatment of "Off" Episodes in Patients with "On/Off" or "Wearing-Off" Effects Associated with Late-Stage Parkinson's Disease after Apomorphine Use for at Least a Three Month Duration, Mylan Pharmaceuticals, 2002
A Multicenter, Multinational, Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial of the Efficacy and Safety of the Rotigotine CDS Patch (2 target doses) in Subjects with Advanced Stage, Idiopathic Parkinson's Disease who are Not Well controlled on Levodopa, Schwarz Biosciences, 2003
A Phase IIIb, Randomized, Double-Blind, Double-Dummy L-Dopa-Controlled, Parallel Group Study of Two Years Treatment with ReQuip CR or Sinemet as Ajunctive Therapy in Patients with Parkinson's Disease Not Optimally Controlled on L-Dopa, GlaxoSmithKline, 2003
A Phase III, Double-Blind, Palcebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients with Early Parkinson's Disease, 2002.
Open-Label, Long-Term. Flexible Dose Study of Safety, Tolerability, and Therapeutic Response in Patients with Parkinson's Disease, 2002.
A Multicenter, Double-blind, Randomized Start, Placebo-controlled, Parallel-group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects.
A Prospective, Multicenter, Randomized, Open Label Study with Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Stalevo on Motor Function and Quality of Life in Patients with Parkinson's Disease with End-of-Dose Wearing Off
Parkinson's Disease (with sleep disturbance, fragmented sleep or excessive daytime sleep) Collaborative Investigator-Initiative Study. A study of the potential role of Xyrem in Parkinson's Disease.
Back to Top
Post Herpetic Neuralgia
A Phase 2B long-term, randomized, open-label, safety and tolerability trial comparing [S,S]-reboxetine (PNU-165442G) with routine care in patients with post herpetic neuralgia (PHN).
(Pfizer Protocol A6061030 EPONA ) A Phase 2B long-term, randomized, open-label, safety and tolerability trial comparing [S,S]-reboxetine (PNU-165442G) with routine care in patients with post herpetic neuralgia (PHN).
Back to Top
Restless Leg Syndrome
A 16-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group Ropinirole CR for RLS (CR-RLS) Phase, Followed by an Open Label Ropinirole Immediate Release (IR) Phase Study to Assess Morning Alertness and Cognitive Function Following Treatment with Ropinirole in Subjects with Restless Legs Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients with Restless Legs Syndrome
A 12-week, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of Ropinirole XR (Extended Release) in patients with Restless Legs Syndrome (101468/205)
A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of once daily XP13512 in patients with Restless Legs Syndrome
A 12-week, double-blind, placebo controlled, twice daily dosing study to assess the efficacy and safety of Ropinirole in patients suffering from Restless Legs Syndrome (RLS) requiring extended treatment coverage.
A 12-week double-blind, placebo-controlled study to assess the tolerability, efficacy and safety of Ropinirole dosed PRN in subjects with Restless Legs Syndrome (RLS) who respond to open-label treatment with Ropinirole. (TREAT RLS PRN)
A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Tolerability of a Dose Escalating Regimen of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS). SKF101468/207. GlaxoSmithKline, 2002
A 12-Week, Double-Blind, Placebo Controlled Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS), 2003
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Saefty and Efficacy of XP13512 in Patients with Restless Legs Syndrome, Xenoport 2004
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25mg, 0.50mg and 0.75mg pramipexole (Mirapex) Administered Orally to Investigate the Safety and Efficacy in Patients with Idiopathic Restless Legs Syndrome for 12 Weeks, Boehringer Ingelheim, 2004
A 12-Week, Double-Blind, Placebo-Controlled, Twice Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage, GlaxoSmithKline, 2004.
A 12-Week Double-Blind, Placebo-Controlled Study to Assess the Tolerability, Efficacy and Safety of Ropinirole Dosed PRN in Subjects with Restless Legs Syndrome (RLS) who Respond to Open-Label Treatment with Ropinirole, GlaxoSmithKline, 2004.
A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome(RLS), 2002.
SP792: A multi-center, randomized, double-blind, placebo-controlled, five-arm parallel group trial to investigate the efficacy and safety of four different trandermal doses of Rotigotine in subjects with idiopathic Restless Legs Syndrome
Back to Top
Sleep Disorders
Efficacy and Safety of Eplivanserin 5mg/day on Sleep Maintenance Insomnia: A 6 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study
A Randomized Double-Blind, Placebo-Controlled Parallel Study of the Efficacy and Safety of (S)-Zopiclone in the Treatment of Adult Subjects with Primary Insomnia Followed by Optional Open-Label Chronic Dosing for up to One Year, Sepracor Inc., 2001
A North-American, 4-Week, Multicenter, Phase IIB Double-Blind, Placebo-Controlled, Randomized, Multiple Dose, Parallel-Group Study of the Efficacy and Safety of 0.5mg, 1.0mg and 2.0mg M100907 Tablets in the Treatment of Sleep Maintenance Insomnia, Aventis, 2004
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem® (sodium oxybate) and Modafinil with Placebo for the Treatment of Daytime Sleepiness in Narcolepsy, 2003.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem® (sodium oxybate) with Placebo for the Treatment of Narcolepsy, 2003
Open Label, Multi-Center Safety Trial Studying the effects of Orally Administered Xyrem® (Sodium Oxybate), 2003
Efficacy and Safety of Eplivanserin 5 MG/Day on Sleep Maintenance Insomnia: A 12 Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Treatment Phase Extension with Eplivanserin for 40 Weeks Period
Back to Top
Stroke
PFO/STROKE STUDY #1: A prospective, multi-center, randomized, controlled trial to evaluate the safety and efficacy of the Starflex Septal Closure System versus best medical therapy in patients with a stroke and/or Transient Ischemic Attack due to presumed paradoxical embolism through a Patent Foramen Ovale.
A Double-Blind, Placebo Controlled, Safety, Efficacy and dose Response Trial of Two Intravenous Doses of BMS-204352 in Patients with Acute Stroke; Bristol-Myers Squibb, 1998.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Hu23FG (LeukArrest) in Patients with Acute Ischemic Stroke; ICOS 1999
Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion (BRAVO); SmithKline Beecham, 1999.SPORTIF V- Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H376/95 Compared with Dose-Adjusted Warfin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation, AstraZeneca, 2000
A Prospective, Multicenter, Randomized controlled Trial to Evaluate the Safety and Efficacy of the StarFlex Septal Closure System Versus Best Medical Therapy in Patients with a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale, NMT Medical, 2003
Back to Top
Other Studies
ORTHOSTATIC HYPOTENSION (100DB8): A multi-center, double-blind, randomized, placebo-controlled, crossover study to assess the clinical benefit of Midodrine Hydrochloride in subjects with moderate to severe Neurogenic Orthostatic Hypotension. (Protocol Version Date: 11 Jun 2004)
CIDP (PROTOCOL C-870): A randomized, double-blind, placebo-controlled, dose-ranging study to determine the safety and efficacy of AVONEX when used in subjects with Polyradiculoneuropathy (CIDP).
POSTHERPETIC NEURALGIA (SHINGLES) STUDY #1 (PROTOCOL XP009): A multi-center, randomized, double-blind, placebo-controlled study assessing the safety and efficacy of XP!3512 in patients with Postherpetic Neuralgia.
DIABETIC NEUROPATHY (Protocol CAPSS-237): A Phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Tramadol HCL/Acetaminophen for the treatment of painful Diabetic Neuropathy.
PAINFUL DISTAL DIABETIC NEUROPATHY (Protocol Schwarz SP742): A multi-center, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of 200, 400 and 600MG/Day SPM 927 in subjects with Painful Distal Diabetic Neuropathy
An Open-Label Multicenter Study to Assess the Safety of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Patients with Pseudobulbar Affect, Avanir Pharmaceuticals, 2002
POSTHERPETIC NEURALGIA (PHN) Protocol A6061026: A 16 Week, Randomized, Double-Blind, Placebo and PreGabalin Controlled, Multi-Center Trial of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia (PHN).
|
